Anthony G. Quinn

Filings by Anthony G. Quinn span 3 companies, the busiest being Spyre Therapeutics, Inc., Generation Bio Co. and Kaleido Biosciences, Inc. In total, 39 filings cover trades dated from 1 December 2017 to 9 February 2026.

Every open-market trade on record is a purchase: 24 purchases worth €1.9M, and no sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 11 option exercises.

Half of the purchases are above €35k and half below. Clusters matter here: 10 out of 24 purchases overlapped with buying by a colleague within 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

Most recently, on 9 February 2026, the filings show a transaction in Generation Bio Co. The last insider purchase was made public on 14 January 2025, 645 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.